Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare ConferencesGlobeNewsWire • 05/14/25
MYGN ALERT: Ongoing Investigation Into Myriad Genetics, Inc. - Contact Levi & KorsinskyAccesswire • 05/14/25
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to ConnectAccesswire • 05/14/25
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Myriad Genetics, Inc. (MYGN)Accesswire • 05/13/25
Lost Money on Myriad Genetics, Inc. (MYGN)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationAccesswire • 05/13/25
Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the InvestigationAccesswire • 05/13/25
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Stockholders to Learn More About the InvestigationAccesswire • 05/12/25
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law FirmBusiness Wire • 05/08/25
Myriad Genetics, Inc. (MYGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationBusiness Wire • 05/08/25
Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a TurnaroundZacks Investment Research • 05/08/25
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. CruzBusiness Wire • 05/08/25
Myriad (MYGN) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 05/07/25
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial GuidanceGlobeNewsWire • 05/06/25
Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health MonitorGlobeNewsWire • 04/30/25
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual MeetingGlobeNewsWire • 04/25/25
Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?Zacks Investment Research • 04/22/25
Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight TestingGlobeNewsWire • 04/21/25
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEOBenzinga • 02/25/25